181 Shares in Illumina, Inc. (ILMN) Acquired by PRW Wealth Management LLC
PRW Wealth Management LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, Holdings Channel reports. The firm acquired 181 shares of the life sciences company’s stock, valued at approximately $53,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sapphire Star Partners LP purchased a new position in shares of Illumina in the fourth quarter worth about $360,000. Financial Enhancement Group LLC purchased a new position in shares of Illumina in the third quarter worth about $400,000. Nan Shan Life Insurance Co. Ltd. purchased a new position in shares of Illumina in the third quarter worth about $52,099,000. Appleton Partners Inc. MA increased its holdings in shares of Illumina by 4.7% in the fourth quarter. Appleton Partners Inc. MA now owns 6,817 shares of the life sciences company’s stock worth $2,045,000 after buying an additional 307 shares during the period. Finally, Pacer Advisors Inc. increased its holdings in shares of Illumina by 18.2% in the third quarter. Pacer Advisors Inc. now owns 13,597 shares of the life sciences company’s stock worth $4,991,000 after buying an additional 2,092 shares during the period. Hedge funds and other institutional investors own 89.25% of the company’s stock.
NASDAQ:ILMN traded down $1.23 during mid-day trading on Thursday, reaching $307.04. 4,407 shares of the company’s stock traded hands, compared to its average volume of 847,321. Illumina, Inc. has a 12-month low of $225.82 and a 12-month high of $372.61. The company has a market cap of $45.32 billion, a PE ratio of 53.80, a P/E/G ratio of 2.17 and a beta of 1.18. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.49 and a quick ratio of 2.27.
Several research analysts have recently commented on the company. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $339.00 price objective on the stock in a report on Friday, February 22nd. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $340.00 to $370.00 in a report on Thursday, January 3rd. BidaskClub downgraded Illumina from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Leerink Swann upgraded Illumina to an “outperform” rating and reduced their price target for the company from $380.00 to $365.00 in a report on Wednesday, January 30th. Finally, Bank of America restated a “buy” rating and set a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $345.82.
In other Illumina news, Director Karin Eastham sold 5,000 shares of Illumina stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $294.08, for a total transaction of $1,470,400.00. Following the sale, the director now directly owns 12,655 shares of the company’s stock, valued at approximately $3,721,582.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction that occurred on Wednesday, December 26th. The shares were sold at an average price of $273.87, for a total value of $903,771.00. Following the sale, the director now directly owns 339,879 shares in the company, valued at $93,082,661.73. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,526 shares of company stock worth $10,501,041. Insiders own 0.54% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Call Option Volume
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.